Optimizing Treatment in Bipolar Disorder: Review & New Directions-View Presentation

Video Transcription

Video Summary

This APA Emerging Topic webinar, moderated by Dr. Vishal Madan, featured Dr. Mark Fry (Mayo Clinic) reviewing how to optimize treatment in bipolar disorder and highlighting new directions. Fry emphasized that effective care depends not only on diagnosing bipolar disorder accurately—often difficult to distinguish early from schizophrenia or unipolar depression—but also on recognizing comorbidities and subtype/specifier patterns that materially change medication choices.<br /><br />He reviewed FDA-approved treatments, noting the dominance of atypical antipsychotics (especially for mania) and the relative scarcity of approved options for bipolar depression. He defined “mood stabilization” as treating one pole without triggering the other and preventing future episodes. Lithium remains a gold-standard comparator, particularly effective for classic euphoric, non–rapid cycling presentations with family history and minimal substance use, but less so for rapid cycling, mixed features, or comorbid substance use—situations where valproate and/or atypical antipsychotics are often preferred. Mixed states warrant caution with antidepressants and often prompt tapering if they worsen instability.<br /><br />For bipolar depression, he underscored limited approved options and mixed evidence for antidepressants, with better support in bipolar II than bipolar I. Comorbidity is “the rule,” especially anxiety and substance use, leading to more complex courses and different prescribing patterns (more benzodiazepines, gabapentinoids, antidepressants; less lithium).<br /><br />He highlighted cardiometabolic burden and emerging metabolic interventions: metformin improving depression in insulin-resistant bipolar patients, and encouraging early safety/weight-loss data for GLP-1 agonists. New research directions include ketogenic interventions, revisiting dopaminergic agents (modafinil and adjunctive amphetamines) for bipolar depression, and strategies to optimize lithium safety (e.g., possible renal protection via SGLT2 inhibitors, interest in lower-dose approaches). Finally, Fry presented BD2 (Breakthrough Discoveries for Thriving with Bipolar Disorder), a multi-site learning health network collecting deep longitudinal data to accelerate precision care and “thriving” outcomes.

Keywords

bipolar disorder treatment optimization

mood stabilization

atypical antipsychotics

lithium therapy

valproate

bipolar depression

mixed features

rapid cycling

psychiatric comorbidity

substance use disorder

cardiometabolic burden

GLP-1 agonists

precision psychiatry learning health network